Publisher Responsibility: The publisher made every effort to ensure accuracy based on publicly available information
Liraglutide and semaglutide have beneficial effects on non-alcoholic steatohepatitis
Eligibility and dosing The tablet is licensed for adults with obesity, with a body mass index (BMI) of 30 or above, or those who are overweight with a BMI between 27 and 30 with at least one weight-related comorbidity, alongside a reduced-calorie diet and increased physical activity
Cosmos Study September 9, 2025 Dual-Team Study Team A:Kersten Bartelt, RNJoe Deckert, PhD Team B:Blaine Franklin, PT, DPTEric Barkley Key Findings At 24 months post-cessation, 56% of semaglutide, 52% of liraglutide, and 55% of tirzepatide patients kept the weight off or lost additional weight
If youve been experiencing both diarrhea and vomiting, rehydration is even more critical